search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Supply chain & logistics


new contracts, or managing to get the suppliers to produce more, healthcare professionals have managed to do their jobs,” Breen says. “That obviously came with huge, huge stress, but they did an admirable job in the face of very traumatic and challenging times.”


She points out that while pressure points during Covid have been unprecedented, shortages and bottlenecks are not actually new, often resulting from quality control issues and recalls. “We know that disruptions happen within our pharmaceutical supply chain all the time – that’s not new. We’ve always had to find ways to adapt and to deal with it,” she continues.


Breen says there were clear problems in early 2020 in the procurement of ventilators and PPE, as well as shortages of hand sanitising gels and some drugs used to manage Covid and other illnesses. However, despite ongoing lumpiness in the vaccines space, the chain continues to absorb sustained pressure. Covid forced supply chains to adapt to fresh demands from hospital systems worldwide, with Breen citing the NHS as a case in point. “The NHS became a much less conservative workforce and it’s now ultra-responsive – that came at a cost and it took its toll on the welfare of the workforce, but from a strategic point of view, it’s become very dynamic and the supply chains helped make that happen.” Breen says trends within the pharmaceutical supply chain in recent years – including digitisation – had helped to build in resilience. The focus, she adds, must now be on adding additional agility and resilience across the network.


Resilience and agility


Digitisation will continue to play a critical role in post-Covid planning and preparedness, though real-time monitoring of pharmaceutical stock was already becoming par for the course prior to the pandemic. “I think we already have a fair amount of control and visibility – for example, in terms of what the wholesaler holds and the quantities distributed to communities, pharmacies and hospitals,” says Breen. “From my research and interactions with wholesalers, they’re very proud of the fact that they can source materials as quickly as they can – if it’s not available, then they will quickly try and switch an order to another site.” She says AI, too, was already being widely integrated into systems prior to the pandemic. “I think there was already a huge appreciation of data mining, having good databases and learning from them. We’ve always had forecasting, but with AI and machine learning, the intelligence is much more profound and incredibly valuable in terms wof designing entire services and manufacturing schedules. A particular area of interest is the cold chain – the supply of pharmaceuticals that must be


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


Talking point: wastage in the supply chain


The supply chain does not end with the delivery of a medication or a device, but with its eventual use, and the topic of wasted vaccines continues to inspire news coverage. Breen doesn’t see the increased focus on Covid vaccine waste having any real impact on the supply chain long term. The system, she says, is already robust in terms of day-to-day medications, and some medicines and vaccines prove more challenging that others to distribute. “We have always had waste within the pharmaceutical supply chain – and if you look at it, cumulatively, it's probably an awful lot of money. But our inventory management systems have become a lot more sophisticated over the years,” Breen adds. There are now teams and resources targeted at reducing wastage, which didn't used to be the case. “We are recording batch numbers, recording quantities, we have staff whose responsibility is to rotate drugs – the level of waste should be a lot lower now than it ever was,” says Breen. “It’s not a new phenomenon, but waste has probably been given more airtime because of Covid-19.”


Even so, a system is needed to ensure surplus medicines – and in particular Covid vaccines – are distributed to other parts of the world, be it via COVAX or other humanitarian channels. “We need to make sure we produce a product that’s going to be used – and if it's not used for its original purpose, then it should be repurposed,” says Breen.


kept at a certain temperature – a particular concern right now with certain Covid vaccines. AI can aggregate several data types, like the weather along a delivery route and the packaging drugs are kept in, to predict the state of the product upon delivery. “AI will keep offering an additional level of robustness in our actions and within our decisions within pharmaceutical supply chains. The information will be more targeted and more useful because it will give you the right information at the right time. You might see more of a ‘just in time’ scenario playing out,” says Breen.


“AI will keep offering an additional level of robustness in our actions and within our decisions within pharmaceutical supply chains.”


Reducing risk


Post-Covid planning will also need to include widespread reviews of supply chain dependencies. Lessons must be learned and acted upon. A 2016 pandemic ‘dry run’ coordinated by the UK government to test systemic healthcare vulnerabilities – dubbed ‘Exercise Cygnus’ – highlighted the need to source and stockpile PPE and ventilators. There is little evidence to suggest the report, which was never published, was ever acted on. Breen says disaster planning is vital. Paracetamol, for example, is an off-patent generic product – it’s a fundamental healthcare provision and should never be in short supply. “It will be a case of always having that contingency plan. So instead of only having one supplier that you can contract, you make sure you hedge your bets, and you have other parties that you can contract as well. I think, in general, we do tend to do that with


57


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65